Detail

Study ID: NRG GI004

Title:

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Colorectal
Stage:
Phase III
Status:
Active - Open to Accrual